MET and Cognitive impairment: Overall, our findings provide evidence that the small-molecule fosgonimeton, via its active metabolite fosgo-AM, may provide therapeutic benefit by positively modulating HGF/MET signaling in dementia and other types of cognitive impairment that involve neurodegeneration and synaptic loss, mitochondrial dysfunction, excitotoxicity, oxidative stress, cholinergic deficits, and neuroinflammation.